Our findings suggest that currently marketed PDE4 inhibitors have the potential to be repositioned for the treatment of CHCHD10S59L-induced ALS-FTD and potentially other related neurodegenerative disorders. The gene discussed is PDE4A; the disease is frontotemporal dementia.